8K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF
1934
Date of Report (Date of earliest event reported): January 3, 2018
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
|
NEVADA
|
001-37761
|
20-5093315
|
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
|
343 Allerton Ave.
South San Francisco, California 94090
|
|
(Address of principal executive offices)
|
(650)
577-3600
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐
Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR 240.12b-2) ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act ☐
Item 7.01
Regulation FD Disclosure
On January 3, 2018, VistaGen Therapeutics, Inc.
(the “Company”) issued a press release announcing that
the U.S. Food and Drug Administration has granted Fast Track
Designation to AV-101, the Company’s lead central nervous
system product candidate for development as a potential adjunctive
treatment for Major Depressive Disorder. A copy of the press
release is attached to this Current Report on Form 8-K as Exhibit
99.1, and is incorporated herein by reference.
On January 8, 2018, the Company began utilizing a new corporate presentation (the
“Corporate
Presentation”). A copy of
the Corporate Presentation is attached as Exhibit 99.2 to this
Current Report on Form 8-K, and is incorporated by
reference herein.
In addition, the Company will be presenting at the
10th
Annual Biotech Showcase Conference in
San Francisco, California on Monday, January 8, 2018 at 4:00 P.M.
Pacific Time.
The information in this Current Report
on Form 8-K, including the information set forth in
Exhibit 99.2, is being furnished and shall not be deemed
“filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the
“Exchange
Act”), nor shall it be
deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by specific reference in such a
filing.
Item 9.01
Financial Statements and
Exhibits.
See
Exhibit Index.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
|
VistaGen Therapeutics, Inc.
|
|
|
|
|
|
Date:
January 8, 2018
|
By:
|
/s/ Shawn K. Singh
|
|
|
|
Shawn
K. Singh
Chief
Executive Officer
|
EXHIBIT INDEX
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
|
Press
Release issued by VistaGen Therapeutics, Inc., dated January 3,
2018
|
|
|
|
Corporate Presentation, dated January 2018
|